Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Ledger.
Press releases published on May 20, 2025
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
GlobeNewswire
·
May 20, 2025
SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Mersana Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, …
BitMEX Launches RLUSD Spot Trading and Margin Support, with a 15,000 RLUSD Reward Pool
GlobeNewswire
·
May 20, 2025
VICTORIA, Seychelles, May 20, 2025 (GLOBE NEWSWIRE) -- BitMEX, the safest crypto exchange, today announced the launch of "The Ripple Effect," an exciting new campaign to introduce significant trading opportunities for its users. Starting 20 May, BitMEX …
Reflect Scientific Receives Over $250,000 in New Orders for High-Performance Freezers from International Biotech and Pharma Clients
GlobeNewswire
·
May 20, 2025
OREM, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of advanced cryogenic and refrigeration technologies, announced today it has received over $250,000 in new orders for its high-performance freezer systems. The …
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
GlobeNewswire
·
May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
Enlivex Selected to Present at Israeli BioMed 2025 Conference
GlobeNewswire
·
May 20, 2025
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage …
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewswire
·
May 20, 2025
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Aventis Energy Provides Recent Exploration Insights at the Corvo Uranium Project
GlobeNewswire
·
May 20, 2025
VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Aventis Energy. (“Aventis” or the “Company”) (CSE: AVE | OTC: VBAMF), is pleased to provide a comprehensive summary of exploration insights and historical data gathered at its Corvo Uranium …
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewswire
·
May 20, 2025
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent …
Praxis Precision Medicines to Participate in Upcoming Conferences
GlobeNewswire
·
May 20, 2025
BOSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
Philikos kondigt de start aan van een klinische fase 1/2-studie met T-Guard® bij patiënten met systemische sclerose
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., een Nederlands biotechnologiebedrijf dat op antilichamen gebaseerde therapieën ontwikkelt voor de behandeling van ernstige immuunziekten, heeft vandaag aangekondigd dat de eerste …
Avicanna Announces Sponsorship of Pilot Phase II Clinical Study Osteoarthritis Pain
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Revival Gold Commences 2025 Field Work and Provides Operational Update
GlobeNewswire
·
May 20, 2025
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce the start of this year’s field work and provide an update on operational activities at the Company’s gold …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Midland Commences a Gold Exploration Program on Its Caniapisc Au Project, James Bay
GlobeNewswire
·
May 20, 2025
MONTREAL, May 20, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an exploration program for gold on its Caniapisc Au project, and also present results from the 2024 till survey, in the Eeyou …
Midland commence un programme d’exploration aurifère sur son projet Caniapisc Au à la Baie James
GlobeNewswire
·
May 20, 2025
MONTRÉAL, 20 mai 2025 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V : MD) a le plaisir d’annoncer le début d’un programme d’exploration pour l’or sur son projet Caniapisc Au, ainsi que présenter les résultats des tills de 2024, dans les …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
Beckley Psytech announces positive topline data from Part 2 of its Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) in combination with SSRIs for treatment resistant depression
GlobeNewswire
·
May 20, 2025
Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was well-tolerated and patients were able to be discharged within …